To achieve profound benefits of AI in drug development & manufacturing, FDA looks to industry for help | Hogan Lovells

A key takeaway from FDA’s discussion papers and recent activities associated with AI/ML is that the agency recognizes the profound potential benefits to advance drug development, manufacturing and compliance, and is open to adapting the current regulatory paradigms to make room for…

Source: www.jdsupra.com – Read more